Jeffrey Rathmell

Twelve current investigators at Vanderbilt University Medical Center and Vanderbilt University are on this year’s list of scientists whose papers have been cited the most frequently by other researchers. Read More

A multidisciplinary team of investigators has received a 2023 Endeavor Award from The Mark Foundation for Cancer Research to support four closely linked projects exploring the fundamental mechanisms that drive the obesity-cancer connection, Read More

A collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine. The group used multiple single-cell technologies, unbiased machine learning and traditional immunological approaches to track cellular and antibody responses in samples collected over time from a cohort of healthy participants. Read More

A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics. Read More

Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years. Read More

Eight Vanderbilt University faculty members have been named 2019 fellows of the American Association for the Advancement of Science, an honor bestowed upon AAAS members by their peers. Read More

Jeffrey Rathmell, Cornelius Vanderbilt Chair in Pathology, Microbiology and Immunology, will be a keynote speaker at the “Targeting Immunometabolism in Autoimmune Diseases and Inflammation” conference at The New York Academy of Sciences in New York City Oct. 22. Read More

The Vanderbilt Center for Immunobiology has relaunched its mission with a greater focus on human immunology, an endeavor supported by additional researchers, more funding support and designation as a Center of Excellence. Read More

Jeffrey Rathmell and colleagues show that a drug that inhibits glutamine metabolism — currently in clinical trials as an anticancer agent — might also be useful as a treatment for inflammatory and autoimmune diseases. Read More

W. Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer. Read More

At the intersection of immunology and metabolism is a burgeoning new field: immunometabolism. It’s an area where Vanderbilt has exceptional strengths, said Jeffrey Rathmell, Ph.D., Cornelius Vanderbilt Professor of Immunobiology. Read More

Nine faculty members who hold endowed chairs were honored and donors were thanked during a festive celebration Sept. 26 at the Student Life Center. Read More

Modulation of T cell metabolism thus may represent a new therapeutic avenue for leukemia patients. Read More

A top Vanderbilt-Ingram Cancer Center (VICC) investigator recently met with Vice President Joe Biden regarding the National Cancer Moonshot Initiative, a major national program to identify, fund and accelerate the most promising research leading to cancer cures. Read More

Jeffrey Rathmell, Ph.D., has been recruited to Vanderbilt University Medical Center (VUMC) to lead a new Center for Immunobiology, a structure supported by the Department of Pathology, Microbiology and Immunology, the Department of Medicine and Vanderbilt-Ingram Cancer Center (VICC). Read More